Metabolism Disorder TRIZ Cases

Lactobacillus paracasei NB23 activates IGF-1 pathways to increase muscle mass while treating metabolic syndrome.

Self-activating acid-carbonate compositions generate carbon dioxide gas to rapidly alleviate hypocapnia symptoms without complex delivery devices.

Adiponectin inhibits carcinogenesis in the liver, addressing insufficient demonstration of blood concentration relationships in obese patients.

Bay 11-7082 inhibits G6PDH to convert white fat cells into brown fat, addressing inadequate obesity therapies.

Crystalline antibody formulations overcome solubility limits by converting proteins to stable solids, enabling high concentration delivery.

Replacing hazardous n-butyllithium with trimethylsilyl bromide enables safe, cost-effective industrial production of pitavastatin calcium.

Controlled crystallization of Palbociclib dimesylate reduces Impurity A levels below 0.1% by excluding contaminants from the crystal lattice.

Peptide inhibitors reduce biological barrier permeability and pro-inflammatory signal secretion to treat celiac disease.

Modified peptide analogs resist enzymatic degradation through targeted amino acid substitutions.

A composition containing auraptene, tangeretin, and medium chain fatty acids suppresses cellular cytotoxicity under heat stress conditions.

A high-purity ethyl icosapentaenoic acid agent suppresses body weight gain through targeted lipid metabolism modulation.

Vitamin D receptor agonists deactivate stellate cells to reduce CXCL12, overcoming stromal barriers and enhancing gemcitabine delivery.

FGF19 variants lower glucose without inducing hepatocellular carcinoma.

Stable co-formulations combine fast-acting insulin with hyaluronan-degrading enzyme to accelerate absorption while maintaining potency for months.

Temperature-responsive amino acid matrices extend drug half-life and stabilize plasma levels by controlling release kinetics.

A composition combining non-sulfamate anticonvulsants, psychotherapeutic agents, and opioid antagonists modulates blood-glucose levels.

Combining phenylbutyrate and benzoate maintains nitrogen excretion while lowering treatment costs.

Tricyclic MetAP2 inhibitors address obesity relapse and side effects by modulating protein translation initiation to sustain weight loss.

A mannosidase enzyme hydrolyzes mannose-1-phospho-6-mannose linkages to uncaps terminal residues on glycoproteins.

Bacterial strains break down plant proteins into peptides and amino acids to increase nutrient absorption in the gastrointestinal tract.

Catalytic hydrogenation replaces stoichiometric agents, eliminating waste and simplifying work-up for pharmaceutical synthesis.

Downregulating OPN3 protein expression in the hypothalamus to upregulate melanocortin receptor signaling.

Modified glycoproteins stimulate fat breakdown while avoiding chronic thyroid overactivation and thyrotoxicosis in metabolic syndrome treatment.

Double-stranded RNAi agents silence the GPR75 gene via RISC-mediated cleavage, addressing obesity treatment limitations.

Bacillus subtilis probiotic supplementation reduces body fat percentage and improves muscle recovery by modulating the gut microbiota and immune response.

A peptide with SEQ ID NO: 1 or 2 suppresses lipid accumulation by regulating pHSL, AMPK-α1, and CGI-58 gene expression.

A weight reduction composition combines milk protein, soybean isolate, whey, collagen, mushroom extracts, okra powder, and MCT microcapsules.

Compounds targeting apolipoprotein CIII-induced calcium channel hyperactivation protect beta cells from apoptosis and limit diabetes development.

A GLP-1 fusion protein extends in vivo half-life through an IgG2 Fc section.

Engineered FGF21 variants utilize specific amino acid substitutions to enhance molecular stability and therapeutic potency.

Lipid nanoparticles deliver mRNA encoding phenylalanine hydroxylase to liver cells.

Anti-IL-6 antibodies bind IL-6 to neutralize its biological effects, reducing cachexia and fever in cancer patients.

Interleukin-22 administration reduces steatosis and transaminase levels, addressing unsatisfactory treatment effectiveness for fatty liver disease.

Anti-IL-6 receptor antibodies block IL-6 signaling to reduce graft damage and improve islet survival in transplantation.

A herbo-mineral formulation combines purified bhasmas with specific herbs to treat diabetes.

A 9-amino-acid HD polypeptide reduces body weight and visceral fat deposition by inhibiting appetite.

Combining phyllodulcin with natural sweeteners reduces sugar content while eliminating bitter aftertaste and maintaining thermal stability.

Enzymatic hydrolysis yields arabinoxylan compositions with specific molecular weights, resolving variability in prebiotic effects from plant fiber extraction.

Double-acylated GLP-1 derivatives attach protracting moieties to lysine residues via specific linkers.

An electromagnetic drive powers a disposable delivery unit, eliminating contamination risks from frequent reassembly of pen-type injectors.

Extraction of specific molecular weight polysaccharides from mycelium improves insulin sensitivity without adverse effects.

Plasminogen administration mitigates lipid-induced injuries by reducing fibrosis and improving myocardial function.

Normal myoblast nuclei fuse with host cells to supply complete genomes, addressing underlying genetic defects that limit current muscle transplant therapies.

A polynucleotide generates hairpin RNA to silence alpha, beta, and omega gliadins in wheat seeds.

High energy infant formula containing prebiotic fibers, probiotic bacteria, and LC-PUFA to promote nutrient absorption.

Conjugating modified GLP-1R agonists with albumin-binding moieties creates a sustained release profile that eliminates the need for dose titration.

A collagen peptide mixture inhibits DPPIV and accelerates GLP-1 secretion through controlled enzymatic degradation.

Isolated oligonucleotides degrade PCSK9 mRNA via RNA interference, lowering circulating LDL-cholesterol while preserving hepatic LDLR function.

A pharmaceutical composition containing dimethyl fumarate achieves specific pharmacokinetic parameters to treat diabetic nephropathy.